Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 7/20 | 0.67 |
| ▸ | ACHE | P22303 | 7/20 | 0.66 |
| ▸ | BACE1 | P56817 | 7/20 | 0.66 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20782569 | 0.86 | ENPP1 (0.66) | ENPP1ACHEBACE1PDE10AMAPK1 | |
| SCHEMBL20771444 | 0.85 | ENPP1 (0.65) | ENPP1ACHEBACE1PDE10AMAPK1 | |
| SCHEMBL14599439 | 0.85 | PDE10A (0.62) | ENPP1ACHEBACE1PDE10APDE3B | |
| SCHEMBL11882354 | 0.85 | ACHE (0.88) | ENPP1ACHEBACE1PDE10A | |
| SCHEMBL24391797 | 0.84 | ENPP1 (0.76) | ENPP1ACHEBACE1PDE10AMAPK1 | |
| SCHEMBL24391608 | 0.84 | ENPP1 (0.67) | ENPP1ACHEBACE1PDE10AMAPK1 | |
| SCHEMBL4965743 | 0.84 | ENPP1 (0.70) | ENPP1ACHEBACE1PDE10AMAPK1 | |
| SCHEMBL7276406 | 0.84 | ENPP1 (0.73) | ENPP1ACHEBACE1PDE10AMAPK1 | |
| SCHEMBL20771446 | 0.83 | ENPP1 (0.92) | ENPP1ACHEBACE1PDE10AMAPK1 | |
| SCHEMBL30446734 | 0.83 | ENPP1 (0.92) | ENPP1ACHEBACE1PDE10AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3941459-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| CN-113924092-B | Quinoline and quinazoline compounds and methods of use thereof | 斯汀格瑞治疗股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| US-11407729-B2 | Quinoline and quinazoline compounds and methods of use thereof | Stingray Therapeutics, Inc. (US) | 2022-08-09 | — | — | US | disclosed |
| US-11407729-B2 | Quinoline and quinazoline compounds and methods of use thereof | Stingray Therapeutics, Inc. (US) | 2022-08-09 | — | — | US | disclosed |
| EP-3941459-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Stingray Therapeutics, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| CN-113924092-A | Quinoline and quinazoline compounds and methods of use thereof | 斯汀格瑞治疗股份有限公司 | 2022-01-11 | — | — | CN | disclosed |
| US-20200299258-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2020-09-24 | — | — | US | disclosed |
| US-20200299258-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2020-09-24 | — | — | US | disclosed |
| WO-2020190912-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Stingray Therapeutics, Inc. (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020190912-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Stingray Therapeutics, Inc. (US) | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299258-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ENPP1, ENPP3, PDE7A | ENPP1 1/4885ACHE 370/4885BACE1 1371/4885 |
| US-11407729-B2 | Quinoline and quinazoline compounds and methods of use thereof | ENPP1, ENPP3, PDE7A | ENPP1 1/4885ACHE 370/4885BACE1 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.